Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02875548 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical Study
A Phase 1 study, sponsored by Epizyme.
- Completed
- Registry status
- Phase 1
- Development phase
- 58
- Enrollment target
NCT02875548 is a Phase 1 study that has completed, run by Epizyme. The registered enrollment target is 58 participants.
The verdict
NCT02875548, a Phase 1 study, has completed, sponsored by Epizyme.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 58 participants
- Enrollment target
Study Summary
This study will provide continuing availability to tazemetostat for people that have previously completed participation in a tazemetostat study, either with monotherapy (single drug treatment) or combination therapy. The aim of the study will be to assess the long-term safety of tezemetostat.
Interventions
- DRUG Tazemetostat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2016-08-30 |
| Est. Completion | 2025-09-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02875548
The ClinicalTrials.gov registry entry for NCT02875548 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Epizyme, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tazemetostat is the first listed.
NCT02875548 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02875548 about?
NCT02875548 is a clinical study titled "A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical Study". This study will provide continuing availability to tazemetostat for people that have previously completed participation in a tazemetostat study, either with monotherapy (single drug treatment) or combination therapy. The aim of the study will be to assess the long-term safety of tezemetostat.
What is the current status of trial NCT02875548?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 58 participants. The study started on 2016-08-30. Estimated completion is 2025-09-26.
What interventions are being tested in trial NCT02875548?
The interventions under investigation include: Tazemetostat (DRUG).
Who is sponsoring clinical trial NCT02875548?
This trial is sponsored by Epizyme, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.